

Press Release

Thursday, June 8, 2017

Strides Shasun Limited (Formerly Strides Arcolab Limited) Strides House, Bannerghatta Road, Bangalore – 560076.

Strides Shasun receives USFDA Approval For Amantadine Hydrochloride Capsules

Product to be launched immediately

Bangalore, June 8, 2017, Strides Shasun today announced that it has received approval from the United States Food & Drug Administration (USFDA) for **Amantadine Hydrochloride Capsules USP, 100 mg.** The product received approval in 15 months under the new GDUFA regime.

According to IMS data, the US market for this product is approximately USD 25 Million with three generic players. The product will be launched immediately.

About Amantadine Hydrochloride Capsules

Amantadine Hydrochloride Capsules are indicated for the treatment of Parkinson's disease and in the treatment of Shingles (Herpes Zoster) to reduce pain.

About Strides Shasun Limited

Strides Shasun, listed on BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has four business verticals, viz., Regulated Markets, Emerging Markets, Institutional Business and Active Pharmaceutical Ingredients.

The Company has global manufacturing foot print with 8 manufacturing facilities spread across three continents including 6 US FDA approved facilities and 2 facilities for the emerging markets. The Company has three dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 85 countries Additional information is available at the Company's website at www.stridesarco.com

For further information, please contact:

Strides Shasun

Shashank Sinha, Managing Director +91 80 6784 0335

Vikesh Kumar +91 80 6784 0827 Kannan N: +91 98450 54745 Sandeep Baid: +91 80 6784 0791

PR Consultancy

Fortuna PR

K Srinivas Reddy: +91 9000527213 <u>srinivas@fortunapr.com</u>

K Priya: +91 9535425418 priya@fortunapr.com